09 December 2024 : Clinical Research
Shiga Toxin-Producing E. coli and Hemolytic Uremic Syndrome: A Study of the 2022 Outbreak in Turkey
Oğuzhan Zengin
ABCDEFG 1*, Burak Göre ABCDEFG 1, Oğuz Öztürk ABCDEFG 2, Muhammet Göv ABCDEFG 1, Enes Seyda Şahiner ABCDEFG 1, Osman İnan ABCDEFG 1, Emra Asfuroğlu Kalkan ABCDEFG 1, Şimal Kösal Cevher ABCDEFG 3, Ahmet Kürşad Güneş ABCDEFG 4, Gülsüm Özet ABCDEFG 5, İhsan Ateş ABCDEFG 1
DOI: 10.12659/MSM.946033
Med Sci Monit 2024; 30:e946033
Table 6 Hemoglobin, platelet, creatinine, and lactate dehydrogenase (LDH) values before and after treatment with eculizumab.
| Eculizumab treatment | Hemoglobin (g/dL) | Platelet (109/L) | Creatinine (mg/dL) | LDH (U/L) | ||||
|---|---|---|---|---|---|---|---|---|
| B.E. | E.1 | B.E. | E.1 | B.E. | E.1 | B.E. | E.1 | |
| Patient 7 | 8.2 | 8.7 | 66 | 41 | 5.4 | 5.06 | 2033 | 2008 |
| Patient 14 | 5.7 | 8.8 | 58 | 75 | 4.5 | 4.3 | 1354 | 1422 |
| Patient 8 | 6.7 | 7.4 | 18 | 24 | 4 | 3.65 | 1560 | 1416 |
| Patient 10 | 7.3 | 6.3 | 57 | 81 | 5.3 | 4.58 | 976 | 448 |
| B.E. – before eculizumab treatment; E.1 – after first dose of eculizumab treatment. | ||||||||